Sep.25.17 | NTCELL
potential disease modifying treatment for Parkinson’s disease.
Weeks away from the
release of Phase IIb results.
NTCELL had
disease-modifying treatment effect equivalent to reversal of 2.8-3.5
years of neurological deterioration in Phase I/IIa trial at 81 weeks
post implantation.
Clinical efficacy of
NTCELL maintained at 130 weeks post implantation in its Phase I/IIa
trial.
If clinical efficacy
shown in Phase IIb trials, commercial sales in New Zealand could
begin in 2018.
Living Cell
Technologies (OTCQX:LVCLY) is a New Zealand-based company whose
primary focus at present is its Phase IIb NTCELL trial of
encapsulated porcine choroid plexus cells for use in the treatment of
patients with severe Parkinson's disease. It has its primary listing
on the ASX, trading under LCT, and is also traded OTC under LVCLY.
It is weeks away
from the release of its Phase IIb results and now has a market
capitalisation of $80 million, with the share price doubling since my
last article on this company (which has more background information).
Its Phase IIb study
is a placebo-controlled trial of various doses of NTCELL up to 6
times the dosage used in its original Phase I/IIa trial where 40
NTCELL microcapsules were implanted only unilaterally.
Figure 1
In the interim,
further data has been released by the company from the patients in
its Phase I/IIa trial, which showed continued benefit from NTCELL in
the motor function component of the UPDRS two years post
implantation. The improvement seen with NTCELL and the duration of
its efficacy would not be expected with a placebo effect as the
clinical course of Parkinson’s disease is to deteriorate with time.
Figure 2
Nenhum comentário:
Postar um comentário
Publicidades não serão aceitas.